Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amid a complex narrative ...
Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Miquita and Jordan discuss Bonnie Blue, Lily Phillips and the idea of queuing for sex. Miquita Oliver and Jordan Stephens ...
Looking to extend the high-flying energy in her singles match, Jones instead found herself down 4-1 in the first set after ...
Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its ...
Down 13 points with seven minutes to play, Buffalo Lake-Hector-Stewart scored 21 of the final 27 points of a Tomahawk-Valley ...
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results